At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 219 enrolled
Drug / intervention
Trelagliptin +1 moredrug
Likely dose
Trelagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Trelagliptin and Daily DPP-4 inhibitor for Type 2 Diabetes. Completed, enrolled 219 participants across 27 sites.
Detailed Summary
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionOct 2017
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartFeb 18, 2017
Primary CompletionOct 21, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.5 years ago
Interventions
Trelagliptindrug
Trelagliptin 100 mg or 50 mg
Daily DPP-4 inhibitordrug
Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin